Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s):  QNTM

Healthcare
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.


CSE:QNTM - Post by User

Quantum BioPharma Ltd > FSD Pharma Drug Pipeline Time Frame Estimates
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(137)
•••
Post by DavidRosenbergon Nov 12, 2021 8:40am
99 Views
Post# 34118692

FSD Pharma Drug Pipeline Time Frame Estimates

FSD Pharma Drug Pipeline Time Frame Estimates
Time lines for the 3 drugs
Phase 2 starts for PEA in 2022
phase 1 starts end of 2022 for the 2 new drug candidates candicates

FSD Pharma is taking a unique approach to deliver “Total Brain Health” to patients in need. Our mission is to treat the millions of people suffering from diseases by bringing innovative therapies to market. Through our wholly-owned subsidiary, Lucid Psycheceuticals, we have the exclusive worldwide rights to patented CNS compounds with the potential to treat progressive Multiple Sclerosis (“MS”). Additionally, FSD is developing a unique psychedelic-based therapeutic aimed to address a multibillion-dollar mental health market.

FSD Pharma has a pipeline of the following 3 drug candidates:

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities